A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days
Status:
Withdrawn
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Currently standard of care for preventing blood clots in total knee replacement patients is
the drug Fragmin which is a daily injection for 10 days after surgery. Patients are in
hospital for 3 to 5 days after total knee replacement surgery and patients are taught in
hospital to do their injections.
The investigators would like to introduce the drug Pradax. Pradax is a Health Canada approved
once a day, oral drug that may prevent blood clots in the patient's leg. In this study the
patient will receive the standard of care injection drug Fragmin while in hospital but on
discharge home the patient will take the oral drug Pradax daily (2 tablets 110mg) for 10
days.